centhaquin
Trade name: Lyfaquin
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02408731)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Alpha-2b adrenergic receptorAGONIST
ADRA2B agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1-(bis(2-quinolyl)ethyl)-4-m-tolylpiperazine
- centhaquin
- centhaquin
- centhaquin
- centhaquine
- quinoline, 2-(2-(4-(3-methylphenyl)-1-piperazinyl)ethyl)-
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02408731 | Phase 1 | Oct 1, 2014 | Jehangir Clinical Development Centre Pvt. Ltd., Pharmazz, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jehangir Clinical Development Centre Pvt. Ltd. | For profit | 1 | 0 | 1 | 2014 |
| Pharmazz, Inc. | For profit | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1